SELLAS Life Sciences Group (SLS) is up 220.1% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely catalyst is SELLAS announcing positive topline data from its pivotal Phase 3 REGAL trial in acute myeloid leukemia. The update appears especially market-moving because the study met its primary endpoint on overall survival, which can materially improve the odds of a future regulatory filing and potential commercialization.
Details:
Sources:
SEC, SELLAS Life Sciences, GlobeNewswire
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$SLS Hedge Fund Activity
We have seen 138 institutional investors add shares of $SLS stock to their portfolio, and 77 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP removed 4,500,000 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $55,395,000
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM removed 2,760,241 shares (-92.4%) from their portfolio in Q3 2026, for an estimated $33,978,566
- STATE STREET CORP removed 2,623,484 shares (-20.2%) from their portfolio in Q3 2026, for an estimated $32,295,088
- JONES FINANCIAL COMPANIES LLLP removed 2,161,983 shares (-93.8%) from their portfolio in Q3 2026, for an estimated $26,614,010
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,653,541 shares (+416.5%) to their portfolio in Q2 2026, for an estimated $24,406,265
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 1,236,571 shares (+218.9%) to their portfolio in Q3 2026, for an estimated $15,222,189
- BLACKROCK, INC. added 1,111,332 shares (+7.4%) to their portfolio in Q3 2026, for an estimated $13,680,496
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.